Prevention Matters: Offit and the Birth of Cancer Genetics

Before Keneth Offit, MD, MPH, became a respected cancer geneticist, he spent most of his time peering through telescopes instead of microscopes.

“I was interested in astronomy and astrophysics at Princeton,” Offit recalled with a smile. “I wasn’t brilliant at it, but I loved it.” His lifelong passion for the stars remains, even if his professional trajectory took him much closer to Earth.

Today, as head of the Niehaus Center for Inherited Cancer Genomics at Memorial Sloan Kettering (MSK) Cancer Center in New York, New York, Offit stands as a pioneer in the field of cancer genetics and prevention. He is credited with identifying the most common BRCA2 mutation in individuals of Ashkenazi Jewish ancestry, and helping to shape how cancer risk is assessed, communicated, and ultimately, reduced. More than 3 decades into a career defined by both scientific rigor and humanistic care, Offit is being recognized as the 2025 Giant of Cancer Care in Prevention and Genetics.

However, his story did not begin with a master plan. It began with a pivot.

From the Cosmos to Cancer

It was Offit’s mother, a physician herself during an era when women in medicine were still pioneers, who nudged him toward a different path.

“She thought medicine would combine the humanities and science,” Offit said. “And she was right.” He changed his focus from astrophysics to biology, eventually earning his medical degree from Harvard Medical
School and a concurrent master of public health degree from the Harvard T.H. Chan School of Public Health. Even then, his interests leaned toward systemic causes of illness, particularly environmental factors that contributed to cancer.

In the early 1980s, Offit worked for the Environmental Protection Agency (EPA) and the Health Effects Institute (HEI), investigating the impact of air pollution on lung cancer. His work came in an era when the environmental movement was gaining steam, with the work of figures like the late Rachel Carson—an American marine biologist, writer, and activist often referred to as the first woman environmentalist—shaping public consciousness around environmental health. But his ambitions were quickly confronted by political realities. A change in presidential administration led to deep cuts in the EPA’s budget and a rollback of environmental regulations.

“They cut the EPA budget by 25%, and that led us to think of public-private partnerships like the HEI and EPA,” Offit explained. After finishing a stint as Chief of Staff at the HEI, he shifted his focus from the external environment to our very own DNA.

Finding a Calling

In the late 1980s, Offit moved to New York to join MSK and Cornell, excited to work under one of the world’s leading cancer epidemiologists, David Schottenfeld, MD, MS. In a twist of academic fate, Schottenfeld was leaving for the University of Michigan just as Offit arrived.

“He said, ‘How would you like to teach my epidemiology course to the Cornell medical students next year?’ ” Offit laughed. “It wasn’t what I came in asking for, but I did it-- for many years. And it was fun.”

Teaching deepened his understanding of cancer epidemiology and planted the seeds for his future work in cancer prevention.

After Offit arrived as a fellow at MSK in 1985, he first encountered the transformative power of genetics, with the field just beginning to recognize the role of mutations of “oncogenes” in cancer development. One of the groundbreaking discoveries of the time was that a chromosomal translocation, a rearrangement of genetic material, could activate an oncogene and cause cancer.

Offit joined the lab of Raju Chaganti, PhD, a leader in this emerging field, and spent the next decade studying genetic abnormalities in lymphomas and leukemias. His work contributed to key publications in journals like the New England Journal of Medicine, laying the foundation for what would become a career defined by translational research.

But Offit’s career would once again take an unexpected turn.

A New Frontier The BRCA Breakthrough

In the early 1990s, Offit joined a collaboration focused on hereditary breast cancer. As Utah researchers traced cancer genes through detailed Mormon genealogies, Offit realized New York had its own unique genetic window:
a large population of Ashkenazi Jewish individuals with higher incidences of certain BRCA mutations.

“We didn’t have Mormon registries [in New York],” he said, “but we had Eastern European Ashkenazi Jewish individuals who made up 20% to 30% of our clinic. It was that way I wound up discovering or characterizing a number of cancer mutations in that population.”

Some of these findings, published in 1996, set the stage for application of cancer genetic counseling to inform cancer prevention.^1-3 Offit would lead the first American Society of Clinical Oncology policy statement following the identification of BRCA1 and BRCA2 mutations, and in 1998, he penned the textbook Clinical Cancer Genetics: Risk Counseling and Management. His 2002 paper in the New England Journal of Medicine demonstrated that risk- reducing ovarian surgery significantly lowered cancer incidence in women harboring BRCA mutations.⁴

Along with influencing clinical practice, these studies helped save lives. Offit remembers a conversation with Francis S. Collins, MD, PhD, then head of the National Center for Human Genome Research, who cited work like Offit’s research as an early example of the Human Genome Project’s tangible benefits.

“He said, ‘We’re saving lives through early genetic screening,’ ” Offit recalled. “That was one of those moments where I felt this work really mattered.”

Building a Field That Didn't Exist

When Offit began his work in hereditary cancer, cancer genetic counseling barely existed as a formal discipline.

“[Initially, this work] was just me sitting down, taking family histories, calculating risk,” he said. Over time, he hired one genetic counselor. As the field grew, Offit built MSK’s genetics program from the ground up,
hiring additional counselors, physicians, and researchers to meet the growing demand for hereditary cancer evaluation. At MSK today, over 18 genetic counselors and 10 physicians staff these clinics.

In time, his work expanded beyond breast and ovarian cancer to other inherited alterations and syndromes, including rare forms of leukemia. He recalled a case involving a nurse whose children had developed acute lymphoblastic leukemia. The family history pointed to a hereditary cause.

“We sequenced everything,” Offit stated. “Eventually we found a mutation in the PAX5 gene.⁵”

He still remembers the phone call he made to the mother, years later: “We figured it out. We found the gene.” It was a moment that epitomized the fusion of science and humanity driving his work. “That’s the best kind of science. When it’s not just a paper, but it’s a person.”

Along with reshaping medicine, Offit’s work has guided the field to face the ethical dilemmas of genomic knowledge. His advancements helped raise questions such as, what do you do when a patient refuses to inform relatives of a shared cancer mutation? Should children be tested for genes they might not need to act on for decades? In the field of reproductive genetics, should there be equal access for parents to be able to select embryos without inherited cancer risk?

“These are not easy questions,” he explained. “We have published on duty to warn, to cascade testing, to the risks of unregulated genetic tests from commercial labs.”

He has written about the limits of the ability of physician to inform at-risk family members when patients choose not to speak to family members. He has explored the moral implications of reproductive genetics, testing in children, and the limitations of direct-to-consumer genetic tests. “These are not just scientific issues,” he said. “They’re deeply personal and ethical ones.”

Offit emphasized that discovery is only part of the equation. Dissemination is where lives are saved. “We can identify a hereditary marker, but if that person’s family doesn’t know or they don’t act on it, we lose the chance to prevent cancer.”

That is why Offit’s work increasingly focuses on cascade testing: identifying and testing relatives of mutation carriers. His federally funded research is using digital tools to notify families and provide consultations, even across state lines.

“We have a paper showing that if we could reach 70% of family members, we’d find nearly all carriers of cancer causing mutations in the US within a decade,”6 he said. “That’s achievable.”

Back To His Roots

Despite his focus on genetics, Offit has not lost his interest in public health.

“We could prevent 50% to 60% of cancers through known behaviors like smoking cessation [and] weight control,” he stated. “Inherited high-risk genetic changes account for maybe 16% of cancers, but it’s uniquely powerful. [With genetics], we’re not asking people to change behavior. We’re asking them to get information that could save their life.”

He believes that success in cancer prevention is not one-dimensional. He explained, “It’s data-driven, yes. But it’s also about empowerment, access, and education. And above all, [it’s about] trust.”

Today, cancer genetics is foundational to nearly every major cancer center. But when Offit began, it wasn’t a recognized specialty. His 1998 textbook, Clinical Cancer Genetics: Risk Counseling and Management, became the blueprint for new programs nationwide. “People would tell me, ‘I’m using your cookbook,’” he laughed.

He is quick to credit colleagues like Judy Garber, MD, MPH, and mentors like Larry Norton, MD, who— similar to Offit—made the shift from lymphoma to breast cancer. He also acknowledges that this journey has never been solitary.

“It’s about building a team,” he said. “You don’t get here alone.”

The Meaning of This Recognition

Receiving the 2025 Giant of Cancer Care Award is more than a personal milestone for Offit. It is a symbol of how far the field has come.

“It’s a teachable moment,” he said. “It reminds oncologists that prevention matters—not just for the patient in front of you, but for their whole family.”

His legacy is not just in the genes he has helped uncover, but in the generations that will not get cancer because of his work. With a path from a stargazing student to an internationally renowned cancer geneticist, Offit exemplifies a story of medicine catching up to science, and of science catching up to the human spirit.

“When you tell someone, ‘You don’t have to get this cancer,’ that’s power,” he added. “And that’s why I love this work.”

References

1. Neuhausen S, Gilewski T, Norton L, et al. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet. 1996;13(1):126-128. doi:10.1038/ng0596-126

2. Offit K, Gilewski T, McGuire P, et al. Germline BRCA1 185delAG mutations in Jewish women with breast cancer. Lancet. 1996;347(9016):1643-1645. doi:10.1016/ s0140-6736(96)91484-1

3. Oddoux C, Struewing JP, Clayton CM, et al. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet. 1996;14(2):188-190. doi:10.1038/ng1096-188

4. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or
BRCA2 mutation. N Engl J Med. 2002;346(21):1609-1615. doi:10.1056/NEJMoa020119

5. Shah S, Schrader KA, Waanders E, et al. A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat Genet. 2013;45(10):1226-1231. doi:10.1038/ng.2754

6. Offit K, Tkachuk KA, Stadler ZK, et al. Cascading after peridiagnostic cancer genetic testing: an alternative to population-based screening. J Clin Oncol. 2020;38(13):1398- 1408. doi:10.1200/JCO.19.02010